Last Updated: 2014-12-04
Decrease Font Size Increase Font Size

NUSAJAYA, Malaysia Dec 3 (NNN-Bernama) -- Malaysia is an ideal destination for biopharmaceutical product manufacturing as the country has a very enabling environment for the industry, says an Indian biopharmaceutical company.

"Prime Minister Najib Tun Razak is very committed towards the development of a high-tech biopharmaceutical industry in the country.

"Malaysia is a stable economy and has policies which investors are looking for.

"The government not only says the right thing but does it," Stelis Biopharma Private Limited Chief Executive Officer Joe Thomas told reporters after the ground breaking ceremony for the construction of Stelis Biopharma (Malaysia) Sdn Bhd's biologics facility at Bio-Xcell Biotechnology Park here today.

He said the construction of the RM201 million facility would be completed in 24 months.

"The multi-products to be manufactured at the facility will cater for the global market. This is a complex facility which involves end-to-end operations.

"It means that we start with research and development, then bulk product manufacturing and finally the manufacture of finished products.

"The facility will produce biologic medical products for cancer and immunogenic disease treatment," he added.